Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-11-21FDA Approved: EPITOL — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for EPITOL (carbamazepine) from Teva Pharmaceuticals USA, Inc. This action approves changes to the p…
-
FDA approval · 2022-11-21FDA Approved: TOPIRAMATE — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for Topiramate (generic Topiramate) from NorthStar RxLLC under an ANDA.
-
FDA approval · 2022-11-17FDA Approved: SEZABY — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved SEZABY (phenobarbital sodium) from Sun Pharmaceutical Industries via an original NDA. It is an anticonvulsant indicated for sei…
-
FDA approval · 2022-11-16FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for divalproex sodium, authorizing changes to the approved generic product unde…
-
CLINICAL_TRIALS trial_result · 2022-11-15Clinical Trial Update: Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus. [Phase 3]
Phase 3 clinical trial investigating tocilizumab for possible immunomodulatory effects in patients with refractory status epilepticus.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-11-15FDA Approved: LEVETIRACETAM — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original application for levetiracetam as a generic drug (Novadoz Pharmaceuticals LLC).
-
CLINICAL_TRIALS trial_result · 2022-11-14Clinical Trial Update: Adjunctive Everolimus Treatment of Refractory Epilepsy [Phase 2]
Phase 2 clinical trial update on adjunctive everolimus for refractory epilepsy.
-
FDA approval · 2022-11-10FDA Approved: DIAZEPAM — Original Application (Fresenius Kabi USA, LLC)
The FDA approved Fresenius Kabi USA, LLC's Original Application for diazepam (generic diazepam). This approval adds a new generic option for…
-
FDA approval · 2022-11-09FDA Approved: CARBAMAZEPINE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for carbamazepine filed by ANI Pharmaceuticals, Inc.
-
FDA approval · 2022-11-08FDA Approved: CARBAMAZEPINE — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application for Carbamazepine submitted by Apotex Corp., a generic formulation.
-
FDA approval · 2022-11-08FDA Approved: CARBAMAZEPINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for carbamazepine from Apotex Corp., approving changes to the approved generic product.
-
FDA approval · 2022-11-08FDA Approved: VIGABATRIN — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for Vigabatrin from Amneal Pharmaceuticals NY LLC, enabling a generic version of the drug.
-
FDA approval · 2022-11-04FDA Approved: OXCARBAZEPINE — Original Application (Bionpharma Inc.)
FDA approved the generic oxcarbazepine under an Original Application for Bionpharma Inc.
-
FDA approval · 2022-11-01FDA Approved: OXCARBAZEPINE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approves a supplemental application for oxcarbazepine submitted by Amneal Pharmaceuticals LLC for the generic product.
-
FDA approval · 2022-10-28FDA Approved: VIGABATRIN — Supplemental Application (Cipla USA, Inc.)
FDA approved a supplemental application for Vigabatrin submitted by Cipla USA, Inc., updating the product's labeling.
-
FDA approval · 2022-10-26FDA Approved: RUFINAMIDE — Original Application (Aurobindo Pharma Limited)
FDA approved Aurobindo Pharma Limited's Rufinamide as a generic drug via an Original Application (ANDA 216549).
-
FDA approval · 2022-10-25FDA Approved: VIGABATRIN FOR ORAL SOLUTION — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' supplemental application to market Vigabatrin as an oral solution, expanding the available dosage f…
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures [Phase 3]
A Phase 3 trial evaluating lacosamide as add-on therapy for children with epilepsy characterized by partial-onset seizures has completed, wi…
-
FDA approval · 2022-10-20FDA Approved: TOPAMAX — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Topamax (topiramate) submitted by Janssen Pharmaceuticals.
-
FDA approval · 2022-10-13FDA Approved: PHENYTOIN SODIUM — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved the original ANDA for phenytoin sodium from Unichem Pharmaceuticals (USA), Inc., providing a generic version of the anticonvuls…
-
FDA approval · 2022-10-12FDA Approved: VIGABATRIN — Supplemental Application (Zydus Pharmaceuticals (USA) Inc.)
FDA approved a supplemental application for Vigabatrin (VIGABATRIN) submitted by Zydus Pharmaceuticals (USA) Inc.
-
FDA approval · 2022-10-12FDA Approved: VIGABATRIN — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for Vigabatrin by Amneal Pharmaceuticals NY LLC under ANDA210155, updating its regulatory status.
-
FDA approval · 2022-10-12FDA Approved: VIGADRONE — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for VIGADRONE (vigabatrin) from Upsher-Smith Laboratories, LLC, authorizing the continued marketing …
-
FDA approval · 2022-10-12FDA Approved: VIGABATRIN — Supplemental Application (Cipla USA, Inc.)
FDA approved a supplemental application for Vigabatrin by Cipla USA, Inc., under ANDA211592 (VIGABATRIN).
-
FDA approval · 2022-10-12FDA Approved: VIGABATRIN FOR ORAL SOLUTION — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' supplemental application for Vigabatrin as an oral solution, adding a new formulation of the antiep…